 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: COPAXONE, GLATOPA (glatiramer acetate) |
|
***************************************************** |
|
#Post#: 2432-------------------------------------------------- |
|
Long-acting glatiramer acetate (GA Depot) for RRMS and PPMS anno |
|
unced |
|
By: agate Date: March 9, 2019, 1:39 am |
|
--------------------------------------------------------- |
|
This new MS drug, to be marketed for RRMS and PPMS, seems to be |
|
a "depot" version of glatiramer acetate (Copaxone), injected |
|
every 4 weeks. Just when it will become available isn't clear: |
|
http://www.globenewswire.com/news-release/2019/02/21/1739488/0/en/Mapi-Pharma-t… |
|
#Post#: 2445-------------------------------------------------- |
|
Re: Long-acting glatiramer acetate (GA Depot) for RRMS and PPMS |
|
announced |
|
By: ewizabeth Date: March 25, 2019, 11:10 am |
|
--------------------------------------------------------- |
|
I bet that will be expensive compared to the injections. |
|
#Post#: 2447-------------------------------------------------- |
|
Re: Long-acting glatiramer acetate (GA Depot) for RRMS and PPMS |
|
announced |
|
By: agate Date: March 25, 2019, 11:26 am |
|
--------------------------------------------------------- |
|
The drug companies usually seem to charge whatever price the |
|
market will bear--and the sky may be the limit. |
|
#Post#: 3693-------------------------------------------------- |
|
Use of GA depot for progressive MS given US patent |
|
By: agate Date: June 24, 2022, 1:11 am |
|
--------------------------------------------------------- |
|
The injection, given every 4 weeks, is intramuscular. The main |
|
justification for bringing this new type of glatiramer acetate |
|
onto the market seems to be that it would be more convenient for |
|
people, and so patient compliance would be improved. |
|
From Multiple Sclerosis News Today (April 2, 2022)--"Use of GA |
|
Depot in Treating Progressive MS Given US Patent": |
|
https://multiplesclerosisnewstoday.com/news-posts/2022/04/1/ga-depot-mapi-pharm… |
|
#Post#: 4346-------------------------------------------------- |
|
US FDA declines to approve GA Depot (yet) |
|
By: agate Date: March 12, 2024, 1:58 pm |
|
--------------------------------------------------------- |
|
The US FDA has declined to approve GA Depot. Apparently more |
|
information is needed, and this may be just a matter of a delay. |
|
From Neurology Live (March 22, 2024)--"FDA Issues Complete |
|
Response Letter for Long-Acting Form of Glatiramer Acetate for |
|
Relapsing Multiple Sclerosis": |
|
https://bit.ly/48QUXIA |
|
***************************************************** |
